| |
original article |
Journal |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
Antibiotics and Chemotherapy |
2024―Jun―21 |
Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19 |
S. Ya. Loginova, V. N. Schukina, S. V. Savenko, V. V. Rubtsov, S. V. Borisevich, D. L. Chizhov, et al. (+5) G. L. Rusinov, E. V. Verbitskiy, V. N. Charushin, S. K. Kotovskaya, V. L. Rusinov |
| 2 |
[GO] |
Antibiotics and Chemotherapy |
2024―Apr―16 |
Epidemic situation and features of accompanying therapy in the treatment of socially significant infectious diseases in penitentiary populations before, during, and after the COVID-19 pandemic |
V. M. Kolomiets, N. A. Polshikova, A. Yu. Petrov, A. L. Kovalenko, E. V. Talikova |
| 3 |
[GO] |
Antibiotics and Chemotherapy |
2024―Apr―16 |
Efficacy and safety of oral antiviral therapy medications in the treatment of moderate and severe cases of COVID-19. Results of a comparative retrospective observational study |
A. U. Sabitov, E. P. Tikhonova, E. V. Esaulenko, P. L. Kuznetsov, A. A. Sharova, T. A. Yelistratova, et al. (+5) Yu. S. Kalinina, I. V. Andreeva, V. V. Basina, E. V. Oleinichenko, A. S. Edin |
| 4 |
[GO] |
Antibiotics and Chemotherapy |
2024―Jan―16 |
Cardiotoxic Drugs Used in the Treatment of COVID-19 |
A. S. Zmitrukevich, A. E. Mamedova |
| 5 |
[GO] |
Antibiotics and Chemotherapy |
2024―Jan―16 |
Present Strategy and Tactics of Antibacterial Therapy for Hospital Infections: Lessons Learned from the COVID-19 Pandemic |
S. D. Mitrokhin, A. V. Aleshkin, A. A. Galitskiy, A. S. Shkoda |
| 6 |
[GO] |
Antibiotics and Chemotherapy |
2023―Dec―27 |
Distribution of Genetic Factors Associated with Severe COVID-19 in Ethnic Groups of the Eastern Caucasus |
S. Р. Abdullaev, К. М.-В. Mammaev, N. Р. Denisenko, I. L. Temirbulatov, A. А. Kachanova, E. V. Mikhaylenko, et al. (+5) А. V. Kryukov, Т. Т. Valiev, К. В. Mirzaev, S. N. Mammaev, D. А. Sychev |
| 7 |
[GO] |
Antibiotics and Chemotherapy |
2023―Dec―27 |
Relief from Toxic Effects of Oxygen Using Succinates in Patients with COVID-19 Undergoing High-Flow Oxygen Therapy |
N. V. Govorova, S. V. Tsilina, I. A. Khilenko, V. V. Rezvykh, Yu. Р. Orlov |
| 8 |
[GO] |
Antibiotics and Chemotherapy |
2023―Oct―23 |
Non-Specific Means of Medical Protection Against COVID-19 |
T. E. Sizikova, E. V. Lebedinskaya, O. V. Chukhralya, A. A. Petrov, V. N. Lebedev, S. V. Borisevich |
| 9 |
[GO] |
Antibiotics and Chemotherapy |
2023―Oct―23 |
Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic |
Y. M. Gomon, A. A. Kolbin, D. S. Budanov |
| 10 |
[GO] |
Antibiotics and Chemotherapy |
2023―Oct―23 |
Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment |
I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. V. Petrova, et al. (+3) E. P. Tkach, A. V. Shipacheva, D. A. Sychev |
| 11 |
[GO] |
Antibiotics and Chemotherapy |
2023―Jul―18 |
A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy |
Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina |
| 12 |
[GO] |
Antibiotics and Chemotherapy |
2023―Jul―18 |
Clinical and Laboratory Characteristics of Patients with COVID-19 on the Background of Cardiovascular Diseases |
Z. A. Kambachokova, Z. A. Akhkubekova, R. M. Aramisova, D. E. Altudova, L. A. Kagazheva, M. A. Shokueva, et al. (+5) A. A. Kambachokova, A. B. Kankulova, A. M. Urusbiev, Yusufzai Abdul Vadzhid, I. A. Kochesokova |
| 13 |
[GO] |
Antibiotics and Chemotherapy |
2023―Feb―11 |
Is There a Need to Widely Prescribe Antibiotics in Patients with COVID-19? |
N. A. Karoli, A. P. Rebrov |
| 14 |
[GO] |
Antibiotics and Chemotherapy |
2022―Dec―29 |
Antiviral Activity of The Preparation Meflokhin® Against COVID-19 |
S. Ya. Loginova, V. N. Shhukina, S. V. Savenko, S. V. Borisevich, K. N. Filin, I. A. Berzin, V. D. Gladkikh |
| 15 |
[GO] |
Antibiotics and Chemotherapy |
2022―Dec―29 |
Antimicrobial Therapy and COVID-19 - the 'Great Confrontation' |
A. A. Zaytsev, A. М. Makarevich |
| 16 |
[GO] |
Antibiotics and Chemotherapy |
2022―Nov―29 |
Antiviral Activity of Interferon alfa-2b and Taurine Combination Against SARS-CoV-2 <i>in vitro</i> |
N. P. Kartashova, A. V. Ivanina, E. A. Glubokova, I. N. Falynskova, A. A. Poromov, I. A. Leneva |
| 17 |
[GO] |
Antibiotics and Chemotherapy |
2022―Nov―18 |
The Effect of Carriage of <i>CYP3A5*3</i> and <i>CYP3A4*22</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 |
I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, et al. (+4) Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV |
| 18 |
[GO] |
Antibiotics and Chemotherapy |
2022―Nov―18 |
The Problem of Comorbid Socially Significant Infections Under The Conditions of The COVID-19 Pandemic |
V. M. KOLOMIETS, N. A. POLSHIKOVA, A. L. KOVALENKO, E. P. PAVLENKO |
| 19 |
[GO] |
Antibiotics and Chemotherapy |
2022―Sep―10 |
Cycloferon as a Means for Prevention, Treatment, and Control of COVID-19: Multidisciplinary and Comparative Historical Aspects |
P. V. MAZIN, R. K. KHAFISIANOVA, V. P. MAZIN, A. A. GALKIN, A. K. OSKANOV |
| 20 |
[GO] |
Antibiotics and Chemotherapy |
2022―Sep―10 |
Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases |
B. B. BELOV, N. V. MURAVYEVA, A. N. KULIKOV |
| 21 |
[GO] |
Antibiotics and Chemotherapy |
2022―Aug―07 |
Medical Rehabilitation of Elderly and Senior Patients with COVID-19-Associated Pneumonia |
M. I. Ivanova, V. M. Ivanov, Yu. M. Shcheglova, A. L. Kovalenko, E. V. Talikova |
| 22 |
[GO] |
Antibiotics and Chemotherapy |
2022―Apr―16 |
Neuroprotective Therapy for Neurological Complications of the Novel Coronavirus Infection COVID-19 |
Ju. L. Lukyanova, S. A. Lukyanov, K. G. Shapovalov |
| 23 |
[GO] |
Antibiotics and Chemotherapy |
2022―Apr―16 |
Antibacterial Therapy of Patients With COVID-19 During The Outpatient and Hospital Stages |
N. A. Karoli, A. V. Aparkina, E. V. Grigoryeva, N. A. Magdeeva, N. M. Nikitina, N. D. Smirnova, A. P. Rebrov |
| 24 |
[GO] |
Antibiotics and Chemotherapy |
2021―Oct―21 |
Seaweed-Derived Sulfated Polysaccharides as Potential Agents for Prevention and Treatment of Influenza and COVID-19 |
N. N. Besednova, T. N. Zvyagintseva, B. G. Andriukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovsky, et al. (+2) L. G. Guseva, M. Yu. Shchelkanov |
| 25 |
[GO] |
Antibiotics and Chemotherapy |
2021―Oct―21 |
Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions |
R. M. Aramisova, Z. A. Kambachokova, Z. A. Akhkubekova, L. L. Logvina, M. M. Sarbasheva, S. M. Chudopal, et al. (+4) L. B. Tlapshokova, L. M. Taukenova, A. R. Tambiev, K. R. Pshukov |
| 26 |
[GO] |
Antibiotics and Chemotherapy |
2021―Oct―21 |
COVID-19 Therapy: the Role of Antirheumatic Drugs |
M. A. Litvinova, N. V. Muravyeva, B. S. Belov |
| 27 |
[GO] |
Antibiotics and Chemotherapy |
2021―Oct―21 |
Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters |
S. V. Chepur, A. V. Smirnova, A. N. Kirienko, I. A. Myasnikova, B. A. Kanevsky, P. V. Sorokin |
| 28 |
[GO] |
Antibiotics and Chemotherapy |
2021―Aug―30 |
Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study |
V. S. Smirnov, I. A. Leneva, T. A. Kudryavtseva, E. B. Fayzuloev, V. A. Zaplutanov, S. V. Petlenko, et al. (+3) N. P. Kartashova, A. V. Gracheva, E. R. Korchevaya |
| 29 |
[GO] |
Antibiotics and Chemotherapy |
2021―Aug―30 |
Local antiviral activity of the drug «Thymogen®», nasal dosed spray, against SARS-CoV-2 coronavirus in vitro |
I. A. Leneva, V. S. Smirnov, T. A. Kudryavtseva, E. B. Fayzuloev, A. V. Gracheva, N. P. Kartashova, et al. (+2) V. A. Zaplutanov, S. V. Petlenko |
| 30 |
[GO] |
Antibiotics and Chemotherapy |
2021―Jun―25 |
Possibilities of Hyperinflammation Correction in COVID-19 |
I. S. Simutis, G. A. Boyarinov, M. Yu. Yuriev, D. S. Petrovsky, A. L. Kovalenko, S. A. Parfenov |
| 31 |
[GO] |
Antibiotics and Chemotherapy |
2021―Jun―25 |
Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach |
K. A. Zykov, E. A. Sinitsyn, A. V. Rvacheva, A. O. Bogatyreva, A. A. Zykova, T. V. Shapovalenko |
| 32 |
[GO] |
Antibiotics and Chemotherapy |
2021―Jun―25 |
Polyphenols Sourced from Terrestrial and Marine Plants as Coronavirus Reproduction Inhibitors |
N. N. Besednova, B. G. Andryukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovskiy, L. N. Fedyanina, et al. (+3) I. D. Makarenkova, I. V. Galkina, M. Yu. Shchelkanov |
| 33 |
[GO] |
Antibiotics and Chemotherapy |
2021―May―07 |
The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19 |
А. U. Sabitov, Р. V. Sorokin, S. U. Dashutina |
| 34 |
[GO] |
Antibiotics and Chemotherapy |
2021―May―07 |
The Prospects of Succinates’ Use under Hypoxic Conditions in COVID-19 |
Yu. Р. Orlov, V. V. Afanasyev, I. A. Khilenko |
| 35 |
[GO] |
Antibiotics and Chemotherapy |
2021―May―07 |
Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population |
А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, et al. (+8) I. V. Samsonova, Е. А. Kovalevskaya, V. V. Parshin, V. V. Pshenichnikova, D S. Fomina, Т. S. Kruglova, М. А. Lysenko, М. А. Dranitsyna |
| 36 |
[GO] |
Antibiotics and Chemotherapy |
2021―Feb―15 |
Cytokine Storm in the Novel Coronavirus Infection and Methods of its Correction |
A. V. Ershov, V. D. Surova, V. T. Dolgikh, T. I. Dolgikh |
| 37 |
[GO] |
Antibiotics and Chemotherapy |
2021―Feb―15 |
Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection |
K. V. Kasyanenko, O. V. Maltsev, K. V. Kozlov, I. I. Lapikov, N. I. Lvov, V. S. Sukachev, et al. (+3) K. V. Zhdanov, P. V. Sorokin, A. K. Ratnikova |
| 38 |
[GO] |
Antibiotics and Chemotherapy |
2020―Nov―23 |
Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19 |
A. U. Sabitov, V. V. Belousov, A. S. Edin, E. V. Oleinichenko, E. P. Gladunova, E. P. Tikhonova, et al. (+3) T. Yu. Kuzmina, Yu. S. Kalinina, P. V. Sorokin |
| 39 |
[GO] |
Antibiotics and Chemotherapy |
2020―Jun―08 |
Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2 |
S. Ya. Loginova, V. N. Shchukina, S. V. Savenko, S. V. Borisevich |
| 40 |
[GO] |
Antibiotics and Chemotherapy |
2020―May―25 |
Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome |
S. Ya. Loginova, V. N. Shchukina, S. V. Borisevich, R. A. Hamitov, V. A. Maksimov |
| 41 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2024―Apr―21 |
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19 |
S. K. Zyryanov, O. I. Butranova, A. A. Abramova |
| 42 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2024―Apr―21 |
Opportunities for using telemedicine based on the COVID-19 pandemic |
F. T. Malykhin |
| 43 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2024―Apr―21 |
Adverse drug events among hospitalized COVID-19 patients. Experience with the Global Trigger Tool |
S. A. Mishinova, A. S. Kolbin, E. V. Verbitskaya, N. P. Alekseeva, Yu. M. Gomon |
| 44 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2023―Apr―19 |
Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19 |
S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, E. V. Verbitskaya, T. I. Galimov |
| 45 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2023―Mar―02 |
Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine |
Y. D. Belousova, V. V. Rafalsky, E. D. Kislova |
| 46 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2022―Nov―15 |
The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective |
A. L. Khokhlov, J. V. Rybachkova |
| 47 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2022―May―02 |
Lifestyle Changes in Medical Students during the COVID-19 Pandemic |
V. A. Sergeeva, T. E. Lipatova |
| 48 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2022―Feb―14 |
Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg |
A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin |
| 49 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2021―Aug―13 |
COVID-19: economic aspects of influenza vaccine prevention |
E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich |
| 50 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2021―Mar―12 |
Socioeconomic and global burden of COVID-19 |
A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov |
| 51 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| 52 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
A. V. Matveev, V. A. Otdelenov, D. A. Sychev |
| 53 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Possibilities for the use of tofacitinib in patients with COVID-19 |
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
| 54 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev |
| 55 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Possibilities for the use of anakinra in COVID-19 |
V. A. Otdelenov, A. V. Matveev, D. A. Sychev |
| 56 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Rationality of routine clinical use of olokizumab in COVID-19 |
V. M. Tsvetov, A. V. Matveev, D. A. Sychev |
| 57 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of colchicine in patients with COVID-19 |
Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev |
| 58 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of umifenovir in patients with COVID-19 |
Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, et al. (+6) K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
| 59 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of vitamin D3 in patients with COVID-19 |
I. N. Sychev, A. V. Matveev, D. A. Sychev |
| 60 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of dipyridamole in patients with COVID-19 |
I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| 61 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Dexamethasone use in patients with COVID-19 |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| 62 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of remdesivir in patients with COVID-19 |
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| 63 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of favipiravir in patients with COVID-19 |
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
| 64 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Use of unlicensed drugs and off-label drug use: focus on COVID-19 |
S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko |
| 65 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge |
A. V. Krykov, V. A. Otdelenov, D. A. Sychev |
| 66 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
V. M. Tsvetov, I. N. Sychev, D. A. Sychev |
| 67 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy |
V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
| 68 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» |
V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev |
| 69 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Rationale for use mefloquine for COVID-19 treatment |
V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
| 70 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention |
K. B. Mirzaev, D. A. Sychev |
| 71 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab |
K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev |
| 72 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Is it possible to use riamilovir to prevent infection and treat COVID-19? |
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| 73 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? |
Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
| 74 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Could canakinumab be used for COVID-19? |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| 75 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 |
K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev |
| 76 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―Oct―28 |
Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel |
V. A. Otdelenov, A. V. Krykov, D. A. Sychev |
| 77 |
[GO] |
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice |
2020―May―30 |
Socio-economic burden of COVID-19 in the Russian Federation |
A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov |
| 78 |
[GO] |
Pharmacogenetics and Pharmacogenomics |
2022―Jan―11 |
Pharmacogenetics of antiviral agents for the treatment of COVID-19 |
I. I. Temirbulatov, A. V. Kryukov, D. A. Sychev |
| 79 |
[GO] |
Pharmacokinetics and Pharmacodynamics |
2021―Jun―23 |
Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues |
O. A. Limanova, O. A. Gromova, L. E. Fedotova |
| 80 |
[GO] |
Real-World Data & Evidence |
2022―Mar―29 |
Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19 |
A. A. Taube |
| 81 |
[GO] |
Real-World Data & Evidence |
2021―Dec―06 |
Paracetamol safety in COVID-19 |
B. K. Romanov |
